Figure 2

Survival for the patients treated with ABR-214936 was compared to a matched simulated control population with equivalent Motzer's characteristics. Overall, median survival (A) was 19.7 months vs 13.7 for the controls and 2-year survival was 42 vs 27%. As a function of drug exposure (B), median survival for the high-exposure group was 26.6 vs 12.1 months for the low exposure group (controls 14.5 and 12.2 months). As a function of IL-2 after the second infusion (C), median survival for the high exposure group was 25.2 vs 10.2 months (controls 14.0 and 13.3 months). Comparing drug exposure, disease control and IL-2 response to survival (D) shows that patients with high IL-2 after the second infusion and high exposure are more likely to have disease control at day 112 and the longest survival. The number of patients in each group is indicated.